Emerging roles of long non-coding RNAs in cancer

Chatterjee, Manjima; Sengupta, Suman

doi:10.1007/s12038-018-9820-z

Cited by 21 publications

(26 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncRNAs are non-coding protein transcripts that have been proved to play a key regulatory role in tumorigenesis, metastasis, and chemotherapy resistance. [11][12][13][14] Increasing evidence has demonstrated the involvement of LncRNA in cisplatin resistance in multiple human cancers. [47][48][49][50][51] In NSCLC, LncRNA SPRY4-IT1 was reported to reverse cisplatin resistance partially through downregulating MPZL-1 via EMT, 52 and LncRNA NORAD was found to increase cisplatin resistance via the miR-129-1-3p/SOX4 axis.…”

Section: Discussionmentioning

confidence: 99%

“…Long non-coding RNA (lncRNA), a type of transcripts with greater than 200 nucleotides in length, has shown an important role in carcinogenesis and has been linked with cancer progression. [11][12][13] In addition, lncRNAs are found to be involved in chemotherapy resistance in multiple human cancers, including LAD. 14,15 LncRNA LINC01116, a novel lncRNA located on chromosome 2q31.1 with 838 nt in length, is reported to contribute to cancer progression.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

Wang¹,

Gao²,

Chen³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) have been found to contribute to cisplatin resistance in several cancers; however, the role of lncRNA LINC01116 in cisplatin resistance remains unknown in non-small-cell lung cancer. This study aimed to examine the contribution of LINC01116 to cisplatin resistance in lung adenocarcinoma (LAD). Materials and Methods: Cisplatin-resistant A549/DDP cells were generated by treatment with cisplatin by dose escalation. LINC01116 expression was compared between A549 and A549/DDP cells, and between cisplatin-resistant and non-resistant LAD specimens. The cell viability, colony formation, proliferation, migration and invasion were measured using MTT and Transwell assays, and cell apoptosis and cell cycle were detected using flow cytometry. The expression of E-cadherin and Vimentin was quantified. LAD xenografts were modeled in nude mice to investigate the role of LINC01116 on the resistance of LAD to cisplatin. Results: MTT assay measured the IC 50 values of 13.49 ± 1.62 and 3.52 ± 1.33 μg/mL for A549/DDP and A549 cells, respectively. LINC01116 was overexpressed in cisplatin-resistant LAD specimens and A549/DDP cells (P < 0.05). Knockdown of LINC01116 inhibited cell viability, proliferation, migration and invasion, promoted apoptosis and enhanced the sensitivity to cisplatin in A549/DDP cells, while LINC01116 overexpression promoted cell viability, proliferation, migration and invasion, inhibited apoptosis and reduced the sensitivity to cisplatin in A549 cells. LINC01116 knockdown resulted in a 2.1-fold increase in E-cadherin expression and a 56% reduction in Vimentin expression in A549/DDP cells, and LINC01116 overexpression resulted in a 45% reduction in E-cadherin expression and a 1.82fold increase in Vimentin expression in A549 cells. Conclusion: Dysregulation of lncRNA LINC01116 expression results in resistance of LAD to cisplatin via the EMT process. Our findings support the oncogenic role of LINC01116 to promote the development of cisplatin resistance in LAD, and LINC01116 may be a novel predictor of poor response to cisplatin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

Wang¹,

Gao²,

Chen³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…LncRNAs have drawn increasing attention in recent years owing to their roles in tumorigenesis [18,29,30]. An increasing number of studies have illustrated that lncRNAs play important roles in OS progression, providing an insight into OS pathogenesis [31][32][33].…”

Section: Discussionmentioning

confidence: 99%

“…However, recent studies have demonstrated lncRNA involvement in various physiological and pathological processes [13][14][15]. LncRNA dysfunction is a key factor in diverse human diseases, particularly cancer [16], with mounting evidence supporting a close association between lncRNAs and human cancers [17][18][19]. LncRNAs may serve both tumor-promoting and tumor-inhibiting functions during carcinogenesis and cancer progression by modulating gene expression at the epigenetic, transcriptional, post-transcriptional, and post-translational levels [20].…”

Section: Introductionmentioning

confidence: 99%

LINC00514 drives osteosarcoma progression through sponging microRNA-708 and consequently increases URGCP expression

et al. 2020

Aging

View full text Add to dashboard Cite

Long intergenic nonprotein-coding RNA 00514 (LINC00514) is upregulated in papillary thyroid cancer and contributes to its aggressiveness. In this study, we thoroughly explored the expression profile, specific functions, and relevant molecular mechanism of LINC00514 in osteosarcoma (OS). Herein, LINC00514 was significantly upregulated in OS tissues and cells, and increased LINC00514 expression was closely correlated with tumor size, TNM stage, and distant metastasis. OS patients with high LINC00514 expression had shorter overall survival than those with low LINC00514 expression. LINC00514 interference inhibited OS cell proliferation, colony formation, migration, and invasion in vitro but promoted cell apoptosis and G0/G1 cell cycle arrest. LINC00514 downregulation hindered OS tumor growth in vivo. Mechanistically, LINC00514 functioned as a competing endogenous RNA by directly interacting with microRNA-708-5p (miR-708) and consequently increasing the expression of upregulator of cell proliferation (URGCP). Both miR-708 knockdown and URGCP restoration partially neutralized anticancer activities of LINC00514 silencing in OS cells. LINC00514 increases URGCP expression by acting as a competing endogenous RNA for miR-708, thus exerting oncogenic roles in OS progression. In conclusion, the LINC00514/miR-708/URGCP pathway may be a promising target for drug discovery in the future.

show abstract

“…Like miRNAs, lncRNAs have vital roles in cellular processes such as transcriptional and post-transcriptional modifications and disruption in their functions may result in disease conditions particularly cancer. Recently, it has been reported lncRNAs could play both oncogenic or tumor suppressing activity during cancer development and also mediate drug resistance/sensitivity in cancer cells [17,18]. Some in vitro and in vivo studies have reported the dysregulation of various miRNAs and lncRNAs during chemoresistance in the CC cells and patients.…”

Section: Introductionmentioning

confidence: 99%

Signaling Pathways in Cervical Cancer Chemoresistance: Are microRNAs and Long-Noncoding RNAs the Main Culprits?

Mousavi¹,

Hemmat²,

Baghi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Cervical cancer is known as one of the most important cancers in women worldwide. Chemotherapy is a standard treatment for advanced/recurrent cervical cancer in which the prognosis of the disease is really poor and the 1-year survival chance in these patients is maximally 20%. However, resistance to anticancer drugs is a major problem in treating cancer. Cervical cancer stem cells are considered as a fundamental cause of chemo and radio-resistance and also relapse after primary successful treatment. Signaling pathways include a wide range of molecular mechanisms contribute to drug resistance. Recently, microRNAs (miRNAs) are announced as a group of molecular biomarkers involving in response to chemotherapy in cancer patients. As the miRNAs, there are some long non-coding RNAs (LncRNAs) which their aberrant expression is considered as a biomarker for monitoring chemoresistance. In this review, we summarized current reports about the involvement of signaling pathways during chemoresistance in cervical cancer. Then, genes that have been demonstrated their involvement during drug resistance in cervical cancer were tabulated. Further, miRNAs that have been reported as biomarkers during treatment are listed. By bioinformatic analysis, we predictedmiR-335-5p and miR-16-5p as the most potential biomarkers for monitoring resistance to chemotherapy. Finally, long non-coding RNAs that have been introduced in recent studies as novel biomarkers during the response to chemotherapy were mentioned.

show abstract

Emerging roles of long non-coding RNAs in cancer

Cited by 21 publications

References 99 publications

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

LINC00514 drives osteosarcoma progression through sponging microRNA-708 and consequently increases URGCP expression

Signaling Pathways in Cervical Cancer Chemoresistance: Are microRNAs and Long-Noncoding RNAs the Main Culprits?

Contact Info

Product

Resources

About